Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

EBV CAR-T Cells for Nasopharyngeal Carcinoma

First Posted Date
2022-12-16
Last Posted Date
2022-12-19
Lead Sponsor
The Affiliated Hospital of Xuzhou Medical University
Target Recruit Count
24
Registration Number
NCT05654077
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

First Posted Date
2022-12-16
Last Posted Date
2024-02-28
Lead Sponsor
Acepodia Biotech, Inc.
Target Recruit Count
42
Registration Number
NCT05653271
Locations
🇺🇸

AdventHealth Orlando, Orlando, Florida, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

and more 4 locations

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

First Posted Date
2022-12-09
Last Posted Date
2024-07-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT05645718
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

First Posted Date
2022-12-09
Last Posted Date
2024-08-26
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
139
Registration Number
NCT05645380
Locations
🇺🇸

The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States

🇺🇸

The University of Kansas Cancer Center - Main Hospital, Kansas City, Kansas, United States

🇺🇸

The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States

and more 4 locations

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

First Posted Date
2022-12-07
Last Posted Date
2022-12-07
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
12
Registration Number
NCT05640713
Locations
🇨🇳

Henan cancer hospital, Zhengzhou, Henan, China

CD30 CAR for CD30+ NSGCT

First Posted Date
2022-12-02
Last Posted Date
2024-10-26
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
18
Registration Number
NCT05634785
Locations
🇺🇸

Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2022-12-01
Last Posted Date
2024-12-20
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
396
Registration Number
NCT05633615
Locations
🇺🇸

Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States

🇺🇸

Highlands Oncology Group - Rogers, Rogers, Arkansas, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

and more 73 locations

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

First Posted Date
2022-11-30
Last Posted Date
2023-08-28
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
10
Registration Number
NCT05631886
Locations
🇨🇳

Biotherapeutic Department of Chinsese PLA Gereral Hospital, Beijing, Beijing, China

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

First Posted Date
2022-11-30
Last Posted Date
2024-02-06
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
15
Registration Number
NCT05631899
Locations
🇨🇳

Biotherapeutic Department of Chinsese PLA Gereral Hospital, Beijing, Beijing, China

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

First Posted Date
2022-11-30
Last Posted Date
2023-07-06
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
38
Registration Number
NCT05631912
Locations
🇨🇳

Biotherapeutic Department, Chinese PLA General Hospital, Beijing, Beijing, China

🇨🇳

School of medicine, Tsinghua University & Changping Laboratory, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy